AVIR earnings date and last-quarter result: last quarter miss, P/E -2.28. Updated 2026-07-23.
Atea Pharmaceuticals (AVIR) Research Hub
Atea Pharmaceuticals (AVIR) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 4.16 USD (+2.97%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.28, market cap 0.38B. This hub links to the full technical, earnings and options research available for AVIR.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 4.16 USD (+2.97%) |
| 52-week range | 3.82 USD – 5.9 USD |
| Trend regime | Range |
| 14-day RSI | 23.9 (Oversold) |
| Trailing P/E | -2.28 |
| Market cap | 0.38B |
| Dividend yield | 0.00% |
Available research for AVIR
Covered Call on AVIR: how it works, illustrative setup around the real 4.16 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on AVIR: how it works, illustrative setup around the real 4.16 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on AVIR: how it works, illustrative setup around the real 4.16 USD price, max profit/loss, breakeven and when to use it. Educational.
AVIR technical analysis: range, last 4.16 USD, RSI 23.9, 52w range 3.82 USD–5.9 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is AVIR in?
Atea Pharmaceuticals (AVIR) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is AVIR in an uptrend or downtrend?
As of 2026-10-26, AVIR is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is AVIR's trailing P/E ratio?
AVIR's trailing P/E is -2.28, with a market cap of 0.38B. See the earnings research page for full valuation detail.